A new study reports spatial predictors that may identify which patients with microsatellite stable (MSS) metastatic colorectal cancer could benefit from chemo-immunotherapy. By mapping treatment response across tissue space, the researchers aim to address a major clinical challenge: MSS tumors have historically shown limited responsiveness to immunotherapy. The approach centers on extracting clinically actionable signals from spatial datasets rather than relying on single biomarkers alone. The findings support the development of stratification tools intended to guide patient selection for combination regimens in MSS mCRC.